- Home
- RBOT vs VRCA Comparison
RBOT vs VRCA Comparison
Compare RBOT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | VRCA |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 87.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RBOT | VRCA |
|---|---|---|
| Price | $1.98 | $6.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $17.00 |
| AVG Volume (30 Days) | 63.3K | ★ 125.6K |
| Earning Date | 01-01-0001 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.71 | $0.39 |
| 52 Week High | $13.75 | $9.82 |
Technical Indicators
Market Signals| Indicator | RBOT | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 51.31 |
| Support Level | $1.76 | $5.22 |
| Resistance Level | $2.41 | $6.44 |
| Average True Range (ATR) | 0.20 | 0.46 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 38.63 | 70.51 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.